Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Additional Gene Therapy Technology Expands Genprex's Portfolio of Oncology LicensesAUSTIN, Texas, April 28, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has signed an exclusive patent license agreement with NYU Langone Health related to the drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid). The therapy is under investi ...